[SCHEDULE 13G/A] Sunshine Biopharma Inc. warrant SEC Filing

Rhea-AI Filing Summary

Amendment No. 1 to a Schedule 13G/A reports that three related Altium entities jointly filed a disclosure concerning Sunshine Biopharma, Inc. The filing names the fund, its investment adviser and the fund's general partner and explains their potential relationships to any securities of the issuer.

The filing explicitly reports 0 shares (0%) beneficially owned by each reporting person and states that the securities were not acquired for the purpose of changing or influencing control of the issuer. The document clarifies parties who could be deemed to have a relationship to beneficial ownership while also affirming that no holdings are reported in this statement.

Insights

Securities Analyst

TL;DR: The filing discloses no beneficial ownership by Altium entities, so there is no immediate change in shareholder structure or voting influence.

The Schedule 13G/A jointly filed by Altium Healthcare Long Short Onshore Fund LP, Altium Capital Management LLC and Altium Healthcare Long Short GP LLC reports 0 shares (0%) beneficially owned. The filing includes customary disclaimers that the reporting persons may be deemed related but affirms that no securities are held for purposes of affecting control. From a market-structure perspective, this is a clarifying, non-actionable disclosure and should be treated as neutral regarding ownership stakes.

Corporate Governance Expert

TL;DR: Joint disclosure improves transparency but reports no stake; thus no governance influence is asserted or implied.

The document provides clear identification of the fund, its adviser and the general partner and confirms that those parties jointly filed the statement while reporting 0 shares (0%). The certification states the securities were not acquired to influence control. This filing therefore documents relationships and intent without indicating any change to governance risk or control dynamics at the issuer.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

SUNSHINE BIOPHARMA, INC.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

867781700

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 867781700

1

Names of Reporting Persons

Altium Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: See Item 4 for a description of the information reported in rows (6), (8), (9) and (11).

SCHEDULE 13G

CUSIP No. 867781700

1

Names of Reporting Persons

Altium Healthcare Long Short Onshore Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: See Item 4 for a description of the information reported in rows (6), (8), (9) and (11).

SCHEDULE 13G

CUSIP No. 867781700

1

Names of Reporting Persons

Altium Healthcare Long Short GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: See Item 4 for a description of the information reported in rows (6), (8), (9) and (11).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SUNSHINE BIOPHARMA, INC.
(b)	Address of issuer's principal executive offices: 333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FL, 33301
Item 2.
(a)	Name of person filing: This statement is jointly filed by and on behalf of each of Altium Healthcare Long Short Onshore Fund LP (the "Fund"), Altium Capital Management LLC, and Altium Healthcare Long Short GP LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management LLC is the investment adviser of, and may be deemed to beneficially own securities, owned by the Fund. Altium Healthcare Long Short GP LLC is the general partner of, and may be deemed to beneficially own securities, owned by the Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each of the Reporting Persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the reporting persons is 152 West 57th Street, FL 20, New York, NY 10019.
(c)	Citizenship: See Item 4 on the cover page(s) hereto.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 867781700
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: N/A
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See responses to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See responses to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on each cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Altium Capital Management LLC

Signature:	Jacob Gottlieb
Name/Title:	CEO
Date:	08/14/2025

Altium Healthcare Long Short Onshore Fund LP

Signature:	Jacob Gottlieb
Name/Title:	Managing Member of Altium Healthcare Long Short GP LLC
Date:	08/14/2025

Altium Healthcare Long Short GP LLC

Signature:	Jacob Gottlieb
Name/Title:	Managing Member
Date:	08/14/2025

FAQ

What does the Schedule 13G/A filed for SBFMW disclose?

It discloses that the reporting Altium entities jointly filed a Schedule 13G/A and that each reports 0 shares (0%) beneficially owned.

Who are the reporting persons on the SBFMW Schedule 13G/A?

The statement is filed jointly by Altium Healthcare Long Short Onshore Fund LP, Altium Capital Management LLC, and Altium Healthcare Long Short GP LLC.

Does the filing indicate an intent to influence control of Sunshine Biopharma (SBFMW)?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What percent of Sunshine Biopharma does Altium report owning?

The filing reports 0% of the class beneficially owned by each reporting person.

Does the Schedule 13G/A identify any members of a group or subsidiary acquisitions?

The filing indicates potential relationships but lists Not Applicable for group dissolution and subsidiary acquisition items in this statement.